Combined Radio- and Chemotherapy for Non-Small Cell Lung Cancer: Systematic Review of Landmark Studies Based on Acquired Citations
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 176
Abstract
The important role of combined chemoradiation for several groups of patients with non-small cell lung cancer (NSCLC) is reflected by the large number of scientific articles published during the last 30 years. Different measures of impact and clinical relevance of published research are available, each with its own pros and cons. For this review, article citation rate was chosen. Highly cited articles were identified through systematic search of the citation database Scopus. Among the 100 most often cited articles, meta-analyses (n=5) achieved a median of 203 citations, guidelines (n=7) 97, phase III trials (n=29) 168, phase II trials (n=21) 135, phase I trials (n=7) 88, and others combined 115.5 (p=0.001). Numerous national and international cooperative groups and several single institutions were actively involved in performing often cited, high-impact trials, reflecting the fact that NSCLC is a world-wide challenge that requires research collaboration. Platinum-containing combinations have evolved into a standard of care, typically administered concurrently. The issue of radiotherapy fractionation and total dose has also been studied extensively, yet with less conclusive results. Differences in target volume definition have been addressed. However, it was not possible to test all theoretically possible combinations of radiotherapy regimens, drugs and drug doses (lower radiosensitizing doses compared to higher systemically active doses). That is why current guidelines offer physicians a choice of different, presumably equivalent treatment alternatives. This review identifies open questions and strategies for further research.Keywords
This publication has 69 references indexed in Scilit:
- Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancerRadiation Oncology, 2013
- Stereotactic body radiation therapy in the re-irradiation situation – a reviewRadiation Oncology, 2013
- CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Stage I Non-Small Cell Lung CancerFrontiers in Oncology, 2012
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI: Journal of the National Cancer Institute, 2011
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407Journal of Clinical Oncology, 2011
- Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancerCancer Treatment Reviews, 2011
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324Journal of Clinical Oncology, 2011
- Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancerCancer, 2011
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010